KFSH unveils AI platform for CAR T-cell therapy screening

King Faisal Specialist Hospital & Research Centre is showing an AI-supported tool at HLTH Europe 2026 in Amsterdam to help clinicians assess eligibility and risk for CAR T-cell therapy. The platform is part of KFSH’s broader push to expand access to advanced cellular therapies through faster, more consistent decision-making. Why it matters: - The platform is aimed at making CAR T-cell therapy screening faster, clearer and more consistent for complex cancer cases. - Better eligibility review can help expand access to advanced immunotherapies while reducing avoidable delays and uncertainty in treatment planning. - KFSH is using the platform to reinforce a broader precision-medicine strategy built around data-driven decisions and specialized care. What happened: - King Faisal Specialist Hospital & Research Centre is showcasing an AI-supported platform at HLTH Europe 2026 in Amsterdam from June 15 to 18. - The tool is designed to strengthen eligibility review and risk assessment for CAR T-cell therapy. - The platform organizes clinical, laboratory, oncology, transplant and treatment-history data into a decision-support framework. - The system helps multidisciplinary teams assess patient readiness, identify risk factors and support planning for advanced immunotherapies. The details: - KFSH has already produced CAR T-cells internally for cancer treatment. - Internal production cut treatment cost from SAR 1.3 million to about SAR 250,000 per treatment. - The hospital says the therapy can now be made available within 14 days. - Before local manufacturing, production outside Saudi Arabia took 21 to 28 days and required shipping and supply-chain steps that could slow access. - KFSH is also advancing CAR T-cell research for acute myeloid leukemia. - KFSH research has explored IL-1RAP CAR T-cells as a potential immunotherapeutic strategy. - Preclinical findings showed antigen-specific activity against AML cells. - The AI platform sits within KFSH’s broader applied AI ecosystem led by its Centre for Healthcare Intelligence. - That center has developed predictive models for clinical and operational use, including models that identify patients at high risk of early complications and support transplant eligibility assessment. Between the lines: - The platform points to a shift from isolated treatment decisions to integrated, data-assisted review across specialties. - The cost and turnaround improvements in CAR T-cell production show why local manufacturing matters for access to highly specialized therapies. - KFSH is positioning its AI and cellular-therapy work as part of global conversations on responsible AI and scalable digital health models. What’s next: - KFSH will use the Amsterdam event to further present its approach to advanced therapeutics and digital health. - The hospital is likely to keep building on its AI and cellular-therapy programs as it seeks broader clinical use and stronger access pathways. The bottom line: - KFSH is pairing AI with in-house CAR T-cell capability to make advanced cancer therapy screening faster, cheaper and more scalable.